BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint blockade. In...
BioCentury | Dec 21, 2018
Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Dec. 19 after the company said late Dec. 18 it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy...
BioCentury | Dec 19, 2018
Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Wednesday after the company said late Tuesday it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy company said...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting IL-30 could help treat prostate cancer. In primary prostate cancer stem-like cells from a mouse model of the disease, an anti-IL-30 antibody or shRNA-mediated IL-30...
BioCentury | Mar 2, 2018
Preclinical News

Targeting IL-30 could treat prostate cancer

In a paper published in Cancer Research , Italian researchers found interleukin-30 (IL-30; IL-27p28) promotes growth and spread of prostate cancer stem-like cells and could be a target for treating the disease. The researchers, who are...
BioCentury | Oct 18, 2017
Translation in Brief

Neutrophil bias

Researchers from the University of Texas Health Science Center have found that IL-27 promotes an anti-inflammatory phenotype in neutrophils that can treat stroke in mice. But safety issues around the recombinant cytokine have the team...
BioCentury | Sep 26, 2017
Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest IL-27 could help treat intracerebral hemorrhage. In a mouse model of intracerebral hemorrhage, IV injection of IL-27 30 minutes post-hemorrhage, followed by daily subcutaneous injections of IL-27 for six days,...
BioCentury | Aug 31, 2017
Translation in Brief

Mouse model herds

With the publication of its first set of data, the International Mouse Phenotyping Consortium (IMPC) has demonstrated it's making strides toward generating and characterizing the phenotypes of knockout models corresponding to the entire mouse genome...
Items per page:
1 - 10 of 78